Literature DB >> 24894300

Trimming the fat in acute ischemic stroke: an assessment of 24-h CT scans in tPA patients.

Alexander J George1, Amelia K Boehme, Casey R Dunn, T Beasley, James E Siegler, Karen C Albright, Ramy El Khoury, Sheryl Martin-Schild.   

Abstract

BACKGROUND: International management of acute ischemic stroke patients treated with intravenous tissue plasminogen activator frequently includes 24-h head imaging. These recommendations stem from the National Institute of Neurological Disorders and Stroke (NINDS) clinical trial protocol regarding the risk of intracerebral hemorrhage post-tissue plasminogen activator administration. Follow-up computed tomography scans on select patients, however, may not effect clinical management, resulting in unnecessary radiation exposure and healthcare costs. AIMS: Our study questions the utility of routine 24-h computed tomography imaging and looks at the National Institute of Health Stroke Scale as a possible clinical screen for selecting candidates for 24-h imaging. Such a tool would result in decreased radiation exposure to the patient and decreased cost to the hospital.
METHODS: Consecutive patients with acute ischemic stroke given intravenous tissue plasminogen activator between June 2008 and December 2011 were retrospectively identified and dichotomized based on change in 24-h National Institute of Health Stroke Scale from baseline. Initial analysis compared patients with National Institute of Health Stroke Scale worsening to those without worsening. Subsequent analysis was limited to patients with a baseline National Institute of Health Stroke Scale ≤10. Baseline demographics and medical history, baseline and 24-h computed tomography findings, medical and/or surgical orders within six-hours of imaging, and antithrombotic administration within 24-48-h postintravenous tissue plasminogen activator were compared between the two groups.
RESULTS: Two-hundred patients met inclusion criteria: No 24-h National Institute of Health Stroke Scale worsening (n = 167) vs. 24-h National Institute of Health Stroke Scale worsening (n = 33). No baseline demographic or admission data differed significantly between the two groups. Patients without 24-h National Institute of Health Stroke Scale worsening had significantly lower incidence of hemorrhagic infarction (10·8% vs. 31·3%, P = 0·0014) on follow-up imaging. Less than 2% of all patients without 24-h National Institute of Health Stroke Scale worsening had a parenchymal hematoma. No patient with baseline National Institute of Health Stroke Scale ≤10 and without 24-h National Institute of Health Stroke Scale worsening had parenchymal hematoma. Patients with 24-h worsening were significantly less likely to receive timely antithrombotic therapy (60·6% vs. 77·8%, odds ratio 0·44, 95% confidence interval 0·20-0·96).
CONCLUSIONS: Our results demonstrate that routine 24-h computed tomography scan in patients without 24-h National Institute of Health Stroke Scale worsening (especially those with baseline National Institute of Health Stroke Scale ≤10) is less likely to yield information that results in a deviation from standard acute stroke care. No patient without worsening and baseline National Institute of Health Stroke Scale ≤10 had parenchymal hematoma on 24-h computed tomography. Application of the National Institute of Health Stroke Scale to distinguish patients who should have 24-h follow-up imaging from those who will not benefit is a potential avenue for improving utilization of resources and warrants further study.
© 2014 World Stroke Organization.

Entities:  

Keywords:  CT scan; acute stroke therapy; cost factors; ischemic stroke; neuroworsening; tPA

Mesh:

Substances:

Year:  2014        PMID: 24894300      PMCID: PMC4602409          DOI: 10.1111/ijs.12293

Source DB:  PubMed          Journal:  Int J Stroke        ISSN: 1747-4930            Impact factor:   5.266


  21 in total

Review 1.  Adjusting for multiple testing--when and how?

Authors:  R Bender; S Lange
Journal:  J Clin Epidemiol       Date:  2001-04       Impact factor: 6.437

Review 2.  Guidelines for the intravenous application of recombinant tissue-type plasminogen activator (alteplase), the second edition, October 2012: a guideline from the Japan Stroke Society.

Authors:  Kazuo Minematsu; Kazunori Toyoda; Teruyuki Hirano; Kazumi Kimura; Rei Kondo; Etsuro Mori; Jyoji Nakagawara; Nobuyuki Sakai; Yoshiaki Shiokawa; Norio Tanahashi; Masahiro Yasaka; Yasuo Katayama; Susumu Miyamoto; Akira Ogawa; Makoto Sasaki; Sadao Suga; Takenori Yamaguchi
Journal:  J Stroke Cerebrovasc Dis       Date:  2013-05-31       Impact factor: 2.136

3.  Utility of repeat brain imaging in stroke.

Authors:  L B Schneider; R B Libman; R Kanner
Journal:  AJNR Am J Neuroradiol       Date:  1996-08       Impact factor: 3.825

4.  Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT).

Authors:  Takenori Yamaguchi; Etsuro Mori; Kazuo Minematsu; Jyoji Nakagawara; Kazuo Hashi; Isamu Saito; Yukito Shinohara
Journal:  Stroke       Date:  2006-06-08       Impact factor: 7.914

5.  Clinical and imaging predictors of intracerebral haemorrhage in stroke patients treated with intravenous tissue plasminogen activator.

Authors:  L Derex; M Hermier; P Adeleine; J-B Pialat; M Wiart; Y Berthezène; F Philippeau; J Honnorat; J-C Froment; P Trouillas; N Nighoghossian
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-01       Impact factor: 10.154

6.  Early hemorrhage growth in patients with intracerebral hemorrhage.

Authors:  T Brott; J Broderick; R Kothari; W Barsan; T Tomsick; L Sauerbeck; J Spilker; J Duldner; J Khoury
Journal:  Stroke       Date:  1997-01       Impact factor: 7.914

7.  Tissue plasminogen activator for acute ischemic stroke.

Authors: 
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

8.  Diagnostic and therapeutic consequences of repeat brain imaging and follow-up vascular imaging in stroke patients.

Authors:  B Ertl-Wagner; T Brandt; C Seifart; M Forsting
Journal:  AJNR Am J Neuroradiol       Date:  1999-01       Impact factor: 3.825

9.  Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group.

Authors: 
Journal:  Stroke       Date:  1997-11       Impact factor: 7.914

10.  Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS)

Authors:  W Hacke; M Kaste; C Fieschi; D Toni; E Lesaffre; R von Kummer; G Boysen; E Bluhmki; G Höxter; M H Mahagne
Journal:  JAMA       Date:  1995-10-04       Impact factor: 56.272

View more
  3 in total

Review 1.  Imaging After Thrombolysis and Thrombectomy: Rationale, Modalities and Management Implications.

Authors:  Felix C Ng; Bruce C V Campbell
Journal:  Curr Neurol Neurosci Rep       Date:  2019-07-06       Impact factor: 5.081

2.  Artificially-reconstructed brain images with stroke lesions from non-imaging data: modeling in categorized patients based on lesion occurrence and sparsity.

Authors:  Stephanie Sutoko; Hirokazu Atsumori; Akiko Obata; Ayako Nishimura; Tsukasa Funane; Masashi Kiguchi; Akihiko Kandori; Koji Shimonaga; Seiji Hama; Toshio Tsuji
Journal:  Sci Rep       Date:  2022-06-16       Impact factor: 4.996

3.  Timing of symptomatic intracerebral hemorrhage after rt-PA treatment in ischemic stroke.

Authors:  Patrick M Chen; Brittney Lehmann; Brett C Meyer; Karen Rapp; Thomas Hemmen; Royya Modir; Kunal Agrawal; Lovella Hailey; Melissa Mortin; Dawn M Meyer
Journal:  Neurol Clin Pract       Date:  2019-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.